Pathology: la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
| la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | |||
| MONALEESA-2, 2016 | MONALEESA-7, 2018 | MONALEESA-3, 2018 | ||
| ribociclib plus endocrine therapy | 1 | T1 | ||
| ribociclib plus fulvestrant | 1 | T1 | ||
| ribociclib plus letrozole | 1 | T1 | ||
| endocrine therapy | 0 | T0 | ||
| fulvestrant | 0 | T0 | ||
| letrozole | 0 | T0 |